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Abstract: In the last years, much work has shown that the most effective repair system of the body is represented by 
stem cells, which are defined as undifferentiated precursors that own unlimited or prolonged self-renewal ability, 
which also have the potential to transform themselves into various cell types through differentiation.All tissues that 
form the body contain many different types of somatic cells, along with stem cells that are called ‘mesenchymal stem 
(or stromal) cells’ (MSC). In certain circumstances, some of these MSC migrate to injured tissues to replace dead cells 
or to undergo differentiation to repair it.The discovery of MSC has been an important step in regenerative medicine 
because of their high versatility. Moreover, the finding of a method to isolate MSC from adipose tissue, so called 
‘adipose-derived mesenchymal stem cells’ (ASC), which share similar differentiation capabilities and isolation yield that 
is greater than other MSC, and less bioethical concerns compared to embryonic stem cells, have created self-praised 
publicity to procure almost any treatment with them. Here, we review the current techniques for isolation, culture and 
differentiation of human ASC (hASC), and describe them in detail. We also compile some advantages of the hASC over 
other stem cells, and provide some concepts that could help finding strategies to promote their therapeutic efficiency.
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Introduction
Stem cells, defined as biological and functional living entities 
(or ‘units’) which are responsible for the organism development 
and the regeneration of organs and tissue systems, are under 
the spotlight for clinical translation. This is because they are 
easily expandable in vitro, since they self-renew, and because 
of their ability to differentiate to multiple cell lineages. Adult 
stem cells represent the most resourceful reservoir of cell 
progenitors, as they are found in potentially any body tissues. 
Mesenchymal stem (or stromal) cells (MSC) have been 
considered one of the most suitable sources for stem cell-based 
therapies because of their multipotential differentiation, by 
using these progenitors to replace or repair damaged musculo-
skeletal tissues (Murray et al., 2014). However, lately, it has been 
shown that MSC can differentiate not only into mesoderm-
derived lineages but also to neuro-ectoderm lineages (Jaiswal et 
al., 1997; Mackay et al., 1998; Shiota et al., 2007; Gojanovich et 
al., 2018), broadening even more their action-span for clinical 
translation. To date, bone marrow supposes the most studied 
type of MSC since their identification in 1974 by Friedenstein 
et. al. (Friedenstein et al., 1974).
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Since the harvesting method for ‘bone marrow 
mesenchymal stem cells’  (BMSC) involves the i l iac 
crest puncture, which can be accompanied by physical 
discomfort, even when the procedure is performed under 
local anesthesia, and because of possible side effects and 
morbidity, researchers have looked for alternative sources 
of MSC. In recent years, new MSC’s tissue reservoirs have 
been recognized in Wharton’s jelly (Wang et al., 2009), 
placenta (In’t Anker et al., 2004), amniotic fluid (Tsai et al., 
2004), menstrual blood (Borlongan et al., 2010), dental pulp 
(Pierdomenico et al., 2005), synovial membrane (De Bari et 
al., 2001)  and adipose tissue (Zuk et al., 2001).
Like bone marrow, the adipose tissue derives from the 
mesenchyme, and consists of an upholding stroma that is 
in fact more easily accessible. The ‘human adipose-derived 
mesenchymal stem cells’ (hASC) are a population of cells 
with the advantage that they can be isolated from surgical 
wastes, because the adipose tissue is routinely discarded in 
abdominal dermolipectomy aesthetic surgery procedures. 
These hASC are derived from the ‘stromal-vascular fraction’ 
(SVF) of adipose tissue and were first described in 2001 by 
Zuk, who named them ‘processed lipoaspirate’ (PLA) (Zuk 
et al., 2001). As human bone marrow stem cells (hBMSC), 
hASC have the same multilineage differentiation capability, 
but adipose tissue is a more convenient available source, 
due to its subcutaneous location, less invasive collection 
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techniques, minimal donor morbidity and higher isolation 
yield. All of these make hASC the most advantageous 
reservoir of hMSC and therefore it is being considered as 
highly promising in up-to-date regenerative medicine.
Along with hASC, the SVF includes other cell types that 
can be separated from them by adherent culture, since non-
adherent cells are eliminated through washing and passaging, 
and non-proliferative cells are overgrown by hASC (Bourin 
et al., 2013), which can be easily expanded in number and 
handled under standard-culture conditions. As stated by 
the International Society for Cellular Therapy (ISCT) and 
the International Federation for Adipose Therapeutics and 
Science (IFATS), the identification of hASC comprises 
three criteria: adherence to plastic, specific surface antigen 
expression and in vitro differentiation into osteoblasts, 
adipocytes and chondroblasts (Dominici et al., 2006), which 
are discussed below.
Newly ground-breaking works are aiming to discover 
hASC natural niche and functions, as well as the possibility 
to manipulate them for therapeutic purposes. For these 
studies to be carried on humans, fluid scientists-doctors 
interactions are essential, as doctors bridge between patients 
and scientists. The initial contact may start in a scientific or 
medical congress or workshop, or researchers may contact 
physicians specifically to ask for tissue donations. Then, 
the protocol, project and informed consent are revised and 
approved by a competent bioethical committee. Once a 
surgery is scheduled, the doctor informs the patient about 
the possibility to donate the tissue, which otherwise would 
be discarded, without neither immediate personal reward 
nor any costs. The scientist has previously provided the 
clinical or hospital with information on how to collect and 
store the samples until pick up. After the samples arrive to 
the laboratory, they are used in research projects, ideally 
multidisciplinary or experimental-computational hybrid 
projects, in which the interpretation of the experimental data 
is used to feedback in silico analysis, that in turn generates 
new questions to be answered experimentally (Fig. 1).
We  re v i e we d  t h e  a s p e c t s  o f  h A S C  i s o l at i on , 
characterization, differentiation and some advantages 
regarding their use over other stem cells. Besides that, we 
introduce some notions and treatment ideas for hASC’s 
successful clinical applications. This work attempts to bring 
to physicians concepts that are born from the basic science, 
trying to merge the knowledge of different disciplines, 
from molecular-cellular-computational biology to material 
engineering and modern medicine. 
hASC isolation
Many hASC isolation protocols have been published during 
the last 15 years. Most of them consist of an enzymatic 
digestion of the adipose tissue to release the cells that 
form the SVF (Zuk et al., 2001). The later consists of an 
heterogeneous cell pellet including the hASC of interest plus 
circulating blood cells, fibroblasts, pericytes, endothelial 
and immune cells, and pre-adipocytes, among others (Lee 
et al., 2013; Nguyen et al., 2016). Recently, we published 
a protocol for hASC isolation, characterization and 
differentiation, with a detailed step by step description for 
these processes (Gojanovich et al., 2018). As all cell culture 
techniques, hASC isolation must be performed aseptically, 
in a biological safety cabinet. Briefly, we use about 100 g of 
freshly harvested subcutaneous adipose tissue obtained from 
abdomen dermolipectomy surgery of healthy patients, who 
has signed an informed consent to voluntarily donate the 
material. Once in the laboratory, the latter is chopped with 
surgical blades, we made several washes with phosphate-
buffered saline (PBS) and centrifuged it to discard mainly 
the red blood cells, and then we incubate the tissue with an 
enzyme preparation. After digesting the tissue, we filter it 
through a 3 mm pore wire mesh to separate the connective 
tissue. The recovered liquid is centrifuged in order to obtain 
the SVF. During this process three liquid phases are obtained: 
(1) an upper yellow lipidic phase, product of the adipocytes 
rupture during processing; (2) a whitish intermediate phase 
containing mature adipocytes; and (3) an aqueous lower 
phase comprising culture medium and a cellular pellet 
corresponding to the SVF. Carefully, the lower liquid phase 
and cellular pellet is recovered and centrifuged. Then, the 
cellular pellet (or SVF) is resuspended in DMEM with 10% 
FBS, seeded in a 10 cm diameter tissue culture plate and 
incubated at 37°C and 5% CO2. The following day, the plated 
cells are washed with PBS buffer and the medium is changed 
to wash away the remaining non-adherent cells. Cells are 
maintained in culture until reaching 90% confluence when 
they are divided for expansion (Gojanovich et al., 2018).
hASC characterization
Because there is no single marker to characterize the 
hASC population, it is necessary to perform a multicolor 
phenotyping analysis with a combination of fluorochrome-
labeled antibodies to specific surface antigens by flow 
cytometry, to evaluate the composition of the isolated 
population. Since there is no common protocol for isolating 
and cultivating MSC among laboratories, the ISCT and 
IFATS issued some criteria for identifying unique populations 
of these cells. According to this, ASC are characterized by 
the expression (>80%) of CD13, CD29, CD44, CD73, CD90 
and CD105 surface antigens, and must lack expression (<2%) 
of CD31, CD45 and CD235a, as primary negative markers; 
while other low or negative markers include CD3, CD11b, 
CD49f, CD106 and PODXL (Bourin et al., 2013). However, 
according to Dominici et al. (2006), who established the 
first ISCT consensus, the phenotype characterization of 
multipotent MSC must include at a minimum the cell surface 
co-expression of the antigens CD105, CD73, and CD90 
(positives) and the absence of hematopoietic and endothelial 
lineage markers CD45, CD34, CD14 or CD11b, CD79a or 
CD19, and HLA-DR (negatives) (Dominici et al., 2006). Since 
the hASC isolated in our laboratory are a subtype of hMSC 
and the characterization kit is intended for use on hMSC, all 
the surface markers analyzed allow us to perfectly identify 
our cell population.
Immunophenotyping analysis in our laboratory is 
achieved by labeling the cells with the BD StemflowTM hMSC 
Analysis Kit (Becton, Dickinson -BD-Biosciences, San Jose, 
CA, USA), which makes possible the characterization of MSC 
based on the Mesenchymal and Tissue Stem Cell Committee 
of the ISCT (Dominici et al., 2006). The hASC populations 
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that we routinely obtain are highly enriched in hASC (≥98%) 
and contain small amounts of other cells (less than 2%) 
(Gojanovich et al., 2018).
Our characterization is comprehensive enough to 
accomplish the consensus of IFATS and ISCT, establishing that 
an ASC phenotyping should include at least two negative and 
two positive markers in the same analysis (Bourin et al., 2013).
FIgure 1. Diagram representing scientific research-clinics positive feedback. Clinical problems guide the construction of experimental and 
computational hybrid projects. Computational biology is used to predict experimental outcomes, optimize experiments planing and use 
of resources. Experimental biology (both in vitro and in vivo) will then generate new questions that feedback in silico studies, and will also 
generate innovations for clinical applications. 
FIgure 2. Osteogenic differentiation of adipose-derived mesenchymal stem/stromal cells. Untreated (UT) cells were maintained in Dulbeco's 
Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), and osteogenic differentiation medium (ODM), 
containing DMEM+10% FBS, plus 10 mM β-glycerophosphate (β-GP), 100 nM dexamethasone (DEX) and 50 µg/mL 2-phospho-L-ascorbic 
acid (AA2P) at days 21 (d21) and 28 (d28) after induction. (A) Alizarin Red Staining of the hydroxyapatite mineralization nodules and (B) 
Alkaline phosphatase staining as an osteogenic biomarker protein (Scale bars: 50 µm). 
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hASC differentiation
Several groups have demonstrated that hASC can differentiate 
into mature adipocyte cells through induction with a drug 
cocktail, which varies between protocols, but usually contains 
dexamethasone, insulin, 3-isobutyl-1methylxanthine (IBMX) 
and indomethacin or thiazolidinedione (TZD) (Bunnell 
et al., 2008). Dexamethasone is a glucocorticoid receptor 
agonist, which sensitize the insulin signaling (Tomlinson et 
al., 2010); insulin is a well-known hormone that stimulates 
glucose uptake; IBMX is a phosphodiesterase inhibitor 
used to increase the cAMP levels (Bunnell et al., 2008); 
both indomethacin and TZD are PPARγ agonists-ligands 
(Tontonoz & Spiegelman, 2008).
Since there is no consensus about the optimal adipocyte 
differentiation protocol, we first tested several cocktail 
formulations on the  3T3-L1 cell line, a well-established murine 
pre-adipocyte cell line widely used for studying adipogenesis 
(Gojanovich et al., 2016). The best drug combination included 
dexamethasone, insulin, IBMX and rosiglitazone (a high-
affinity PPARγ ligand, member of the TZD family). Next, we 
adapted the NIH 3T3-L1 adipogenesis protocol described in 
Gojanovich et al., (2016) for hASC adipogenic differentiation 
by introducing cycles of induction and maintenance medium, 
as detailed in Gojanovich et al. (2018).
To evidence the lipid droplets accumulation, we 
routinely use Oil Red O (Biopack, Buenos Aires, Argentina), 
which specifically stains triglycerides and cholesteryl 
oleate (Ramírez-Zacarías et al., 1992; Masone et al., 2017; 
Gojanovich et al., 2018).
The osteogenic differentiation of hASC requires 
a  speci f ic  t reatment  of  conf luent  monolayer  with 
dexamethasone, β-glycerophosphate and ascorbic acid during 
three to four weeks to change their characteristic fibroblastoid 
morphology to a multilayer culture of elongated cells, typical 
of this differentiation (Bunnell et al., 2008; Langenbach & 
Handschel, 2013). Based on literature information, combined 
with our results, the optimal concentration for osteogenic 
differentiation drugs are 100 nM  dexamethasone, 50 µg/mL 
2-phospho-L-ascorbic acid and 10 mM β-glycerophosphate 
(Langenbach & Handschel, 2013), replacing the osteogenic 
medium every two or three days. Briefly, dexamethasone 
induces hASC osteoblast differentiation by activating 
WNT/β-catenin signaling-dependent RUNX2 expression; 
ascorbic acid facilitates differentiation by promoting Type I 
collagen (COL1A) secretion; and β-glycerophosphate favors 
extracellular matrix (ECM) mineralization by serving as a 
local source of inorganic phosphate ions.
Detection of calcium deposition  after induction of 
differentiation can be detected by Alizarin Red S staining 
(Biopack, Buenos Aires, Argentina), since the dye forms a 
complex with the Ca10(PO4)6(OH)2 of the ECM in a chelation 
process, visualized as red mineralizing nodules (Bunnell et al., 
2008) (Fig. 2A). To determine the alkaline phosphatase (ALP) 
activity as an osteogenic protein biomarker, we perform 
ALP staining using BCIP® (5-bromo-4-chloro-3-indolyl 
phosphate, Calbiochem, San Diego, CA, USA) which is 
hydrolyzed by the enzyme forming an intermediate product, 
that is then oxidized by the NBT (nitro blue tetrazolium, 
BDH Chemicals Ltd., Poole England, UK), generating an 
insoluble violet precipitate (McGadey, 1970) (Fig. 2B).
To assess chondrogenic differentiation, the micromass 
culture technique (Denker et al., 1995) is usually employed. 
Normally, a concentrated cell suspension is seeded in a 
24 well plate and allowed to attach at 37°C for 2 hours. 
Cell-to-cell interaction in high cell density micropellets 
is critical to achieve a propitious chondrogenic process 
(Vinatier et al., 2009). After that, the chondrogenic medium 
containing TGF-β, insulin, transferrin, sodium selenite, 
dexamethasone, proline, and ascorbic acid is gently added 
so that the cell nodules are not detached (Zuk et al., 2001). It 
is well documented that TGF-β increases the proteoglycans 
and Type II collagen (COL2A) synthesis rates and also 
cell proliferation (Awad et al., 2003; Vinatier et al., 2009); 
insulin, transferrin and sodium selenite, commonly known 
as ITS supplement medium, serves to enhance nutrition 
transportation into the inner part of the cartilage, promotes 
chondrocyte dedifferentiation process, and also production 
of polysulfonate glycosaminoglycans (GAGs) and COL2A 
(Liu et al., 2014); dexamethasone increments the proline 
uptake and upregulates aggrecan, proteoglycans and COL2A 
biosynthesis via SOX-9 transcription factor expression 
(Awad et al., 2003); proline and ascorbic acid are necessary 
as substrate and co-factor, respectively, of the prolyl-
lysyl hydroxylase, a key enzyme in collagen biosynthesis 
(Temu et al., 2010). Cultures must be maintained with the 
chondrogenic medium during one month, with medium 
changes every two or three days.
The presence of ECM  proteins characteristic of hyaline 
articular cartilage, like proteoglycan, can be confirmed by 
Alcian Blue, Toluidine Blue O or Safranin O staining (Jubb 
& Eggert, 1981). Those are basically cationic dyes that form 
complexes with the anionic glycoconjugates of the cartilage 
ECM, such as GAGs and proteoglycans. The intensity of the 
staining is proportional to the amount of glycoconjugates in 
the hyaline cartilage (Terry et al., 2000).
Clinical applications
Since the beginning of the 21st century, when the ASC were 
discovered, they appeared as particularly useful in the field 
of regenerative medicine because of their many advantages 
compared to other types of stem cells (Zuk et al., 2001). 
First of all, ASC can be easily harvested with minimal donor 
morbidity through liposuction or dermolipectomy surgery. 
The harvest method implies a higher yield on ASC  isolation, 
and their capability of differentiation is similar to other MSC 
(Feisst et al., 2015). Moreover, ASC are not as questioned as 
embryonic stem cells because they are derived from adult 
adipose tissue (Dai et al., 2016).
Probably related to these advantages, it is noteworthy 
the number of clinical trials being accomplished at the 
moment with ASC. If we look for “adipose-derived stem cells” 
on the US National Institutes of Health (NIH) website (http://
www.clinicaltrials.gov), we can find that there are 112 studies, 
among which 42 are currently open. The great potential 
of stem cells to treat several human diseases like cancer, 
Parkinson’s disease, diabetes mellitus, Crohn’s disease, heart 
failure, autism, burns, amyotrophic lateral sclerosis, spinal 
cord injury, erectile dysfunction, premature ovarian failure, 
osteoarthritis, autoimmune diseases, etc. is well-known. 
A huge commercial “stem cell based therapies” industry is 
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being built based on this potential, and it is alarming the 
increased number of companies that conveniently sell stem 
cells treatments that have not been proved in clinical trials 
because of the lack of regulation (Martell et al., 2010) in 
many countries. Indeed, a “stem cell tourism” has emerged to 
travel to less regulated countries to get treatments that are not 
approved in the more regulated ones.
In Argentina, there is still no legislation regarding 
the clinical use of stem cells. Nevertheless, the Instituto 
Nacional Central Único Coordinador de Ablación e 
Implante (INCUCAI) has declared that “the only stem 
cell treatment that has demonstrated safety and scientific 
efficacy is transplantation of hematopoietic progenitor 
(stem) cells in cases of onco-hematological diseases and out 
of this treatment there is no clinical evidence or treatments 
established at national and international levels, who have 
demonstrated the effectiveness of using stem cells to cure 
other diseases”.
Along with their isolation-related qualities, hASC 
are highly attractive in the medical field, since they do not 
present surface molecules of class II major histocompatibility 
complex (MHCII), which allows them to be transplanted 
across allogenic barriers without eliciting an immune 
response (Le Blanc et al., 2003; Tse et al., 2003; De Miguel 
et al., 2012; Huang et al., 2016). If the hASC are to be used 
in clinics, it is mandatory to replace all traditional culture 
reagents by defined xeno-free reagents or, alternatively, more 
recently developed techniques which avoid the use of FBS or 
other animal sera are to be used (Cimino et al., 2017).
Hereafter, we describe a series of hASC’s potential 
clinical applications in different medical areas, including their 
pros and cons (Fig. 3).
FIgure 3. Human adipose-derived mesenchymal stem/stromal cells (hASC) potential clinical applications in different medical areas. 
As detailed in the article, hASC can be used to treat a wide variety of diseases. The fields with current greater advances are plastic and 
reconstructive surgery, bone and joint repair, 3D tissue printing and oncological therapies. 
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Oncology
Several uses of hASC for oncolytic therapy have been 
proposed on the basis of their ability to home/migrate. But, 
what is it the homing/migration of the hASC and why does 
it happen? In 2009, Karp and Teo defined homing as “the 
arrest of MSC within the vasculature of a tissue followed 
by transmigration across the endothelium” (Karp & Leng 
Teo, 2009). MSC express cytokines, chemokines and growth 
factors receptors on their surface, that allow them to migrate 
to the site of disease or injury by chemotactic gradients, 
which guide them to the damaged tissue (Cho et al., 2009). 
Although the homing/migration of the ASC has been tested 
in most cases, it seems that this capability is dependent 
on the injection method, and even when they manage to 
reach the damaged tissue, the amount grafted there is too 
low compared to the amount injected (De Becker and Riet, 
2016). Controversially, Anjos-Afonso et al. (2004) transduced 
murine MSC with a lentiviral eGFP containing vector to track 
them within mice and found that mMSC migrate mostly 
to the lung, but also to other organs like liver, muscle and 
kidney, even in the absence of injury, and that they acquire 
the residing tissue morphology and antigen expression 
(Anjos-Afonso et al., 2004).
For cancer treatment, MSC have been proved as 
vehicles to deliver several anti-cancer therapies. Some 
examples include the expression of anti-cancer proteins 
(such as interleukins, pro-apoptotic proteins, etc.), the 
production of pro-drugs activating enzymes, the delivery of 
oncolytic viruses and nanoparticles containing chemo- or 
radiotherapies (Bhere and Shah, 2015). Even though these 
treatments seem promising,  we must consider that  they can 
be toxic even to the MSC themselves and also that the MSC 
can enhance the tumor severity because of their angiogenic 
capacity, or they may even generate a new tumor elsewhere 
(Fiala, 1968; Blanton et al., 2009). Recently, a novel strategy 
is being tested, which consists in MSC encapsulation (Murua 
et al., 2008). This approach requires not only the expertise of 
physicians and molecular biologists, but also bioengineers, 
thus a multidisciplinary team to deal with a bigger challenge. 
Drug screening and disease modeling
Despite their source, the extent of stem cell’s applications 
covers a wide scope. The advantages of their use in the 
field of drug screening rely on the promise of developing a 
more trustworthy, accelerated and profitable drug discovery 
process. Until 2015, less than 10% of the drugs that enter 
Phase I clinical trials,  end up being approved successfully 
for disease treatment (Seruga et al., 2015). This information 
highlights the need to expand and improve the spectrum of 
new drug testing.
Most primary drug screening tests are carried out with 
cells grown on two-dimensional tissue culture plates or flasks. 
The aim of this method is to identify the largest number of 
hits, but it fails to mimic the niche complexity. That is when 
appears the need of using methods, which simulate better the 
in vivo situation.
Since the use of animal models in this research area 
tends to lead to drug failure and side-effects when translated 
to humans, due to interspecies differences (Miranda et al., 
2018), it is necessary to address new approaches. In this 
matter, 3D assays could shorten the gap between primary 
screening and human trials, providing tools such as cellular 
aggregates or spheroids, the new developed constructs 
termed “organoids” and the most recently created organ-on-
a-chip platforms (Ranga et al., 2014; Miranda et al., 2018).
Cellular aggregates or spheroids for screening purposes 
are a powerful tool since there is no need to provide any 
adhesion matrices for cell adhesion. As an obstacle, they 
present heterogeneity and cellular disorganization, which leads 
to poor control of the size and differentiation of the cells within 
the spheroids (Ranga et al., 2014; Miranda et al., 2018).
The optimal assessment of drug effects and disease 
modeling should be carried out on models which best 
mimic the whole-organ composition, physiology and 
microenvironment, which implies a heterogeneous but 
uniformly distributed and organized cellular composition. 
For that matter, organoids, defined by Lancaster and 
Knoblich (2014) as “a collection of organ-specific cell types 
that develop from stem cells or organ progenitor cells to 
form an organ-like tissue exhibiting multiple cell types that 
self-organize to form a structure not unlike the organ in 
vivo” (Lancaster et al., 2014), are the new gold standard in 
drug screening and disease modeling. Their potential over 
spheroids lies in that they better simulate the migration, 
angiogenesis, and bioavailability of drugs when crossing 
biological barriers (Ranga et al., 2014). On the other hand, 
the current limitation of organoid culture is the scale-
up production, since their formation is time-demanding 
(Miranda et al., 2018).
The need to fill the gap between in vitro testing and 
humans has led to the development of multi-organ platforms. 
Organs-on-a-chip provides a device which comes to improve 
the assessment of the interaction of the drugs and their 
metabolites with different parts of the body, recapitulating 
some other aspects of the human physiology like absorption, 
metabolic processing and toxicity. Nevertheless, since their 
accessibility is limited, its application is still restrained 
(Miranda et al., 2018). 
Bone regeneration
The main challenge in the field of bone repair is to improve 
the osseointegration of implants in large bone injuries. 
Unlike small bone defects, where the human body has the 
innate ability to repair, bone healing in large bone injuries is 
delayed or absent. Before detailing some clinical strategies to 
reduce post-operative complications associated with graft-
versus-host disease in bone transplants, it is necessary to 
explain what we mean when we speak of osseointegration. 
This concept was first introduced by Professor Per-Ingvar 
Branemark (1969), who explained this process as “a direct 
structural and functional connection between ordered 
living bone and load-carrying endosseous implant at the 
light microscopic level” (Jayesh and Dhinakarsamy, 2015). 
In order to enhance osseointegration, it is of outstanding 
relevance to define three features that should have bone 
grafts: (1) osteogenesis: is the process by which new bone 
is synthesized, it requires cells with bone differentiation 
capacity ; (2) osteoinduction :  MSC are recruited to 
differentiate, this recruitment needs the regulation of growth 
factors and cytokines; (3) osteoconduction: is the three-
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dimensional growth of capillaries, perivascular tissue and 
stem cells from the receiving area of the host to the graft, 
generating a scaffold with the niche characteristics that favors 
the host-graft interface for regeneration (Zárate-Kalfópulos 
and Reyes-Sánchez, 2006).
Some cases in which MSC per se have been enough to 
repair bone defects (Lee et al., 2015; Fu et al., 2016; Zou et 
al., 2016) have been shown, but in general, the gold standard 
therapeutic strategy is to combine the components to induce 
bone growth and regeneration, taking into account the three 
above mentioned characteristics that should have bone 
grafts (Romagnoli and Brandi, 2014). Most suitable scaffolds 
must have pores that allow cell infiltration and extracellular 
matrix deposition; permit incorporation and control drugs, 
growth factors and bioactive components release; and should 
be comprised of resorbable materials so that they would be 
replaced by newly-formed bone over time (Romagnoli and 
Brandi, 2014).
There are basically two types of polymer scaffolds. 
Natural polymers are derived from biological sources, such 
as collagen, hyaluronic acid and alginate. These have the 
advantages of being biocompatible and bioactive, promoting 
cell attachment and growth. However, their liabilities are that 
they present a high risk of pathogen transmission, are difficult 
to engineer, and they exhibit batch-to-batch variability. On 
the other hand, synthetic polymers are far more malleable 
and have defined chemical formulation, so they can be easily 
sterilized. Nevertheless, despite their stability, synthetic 
materials can elicit undesirable inflammatory responses in 
vivo since they are not bioactive (Agarwal and García, 2015). 
Joint repair
To understand the requirements of joint repairment it is 
necessary to recognize what are the symptoms of articular 
cartilage damage. Pathologies like osteoarthritis and 
rheumatoid arthritis begin to manifest by pain, swelling, 
limited motion and go on with cartilage degeneration (Nam 
et al., 2018). Progress of the illness severity is accompanied 
by changes that occur within the articular cartilage, especially 
regarding its composition.
There are mainly three types of cartilage: elastic cartilage, 
hyaline cartilage and fibrocartilage. Cartilage from joints 
is composed by hyaline cartilage, whose smoothness and 
flexibility are intermediate between elastic- and fibrocartilage 
(Nam et al., 2018). To add more complexity, the articular 
hyaline cartilage has different compositions of ECM according 
to its depth. Chondrocytes located at the surface of the articular 
cartilage secrete a protein named lubricin, which lubricates 
the joint. In the middle zone, chondrocytes mainly produce 
aggrecan and, in deeper regions, ECM is mostly composed by 
proteoglycans (Sakata et al., 2015; Nam et al., 2018). 
Since chondrocytes are the only cell type and constitute 
1-5% of the articular cartilage, and the joint, unlike most 
tissues, is avascular, it is almost impossible to repair an 
articular lesion regenerating hyaline cartilage. So when there 
is an imbalance between the catabolic and anabolic factors 
that lead to cartilage degradation, chondrocytes are replaced 
by fibroblast-like cells at the beginning and afterwards hyaline 
cartilage is replaced by fibrocartilage. These events prompt 
osteophyte formation, inflammation, rigidity and additional 
pain (Sakata et al., 2015; Nam et al., 2018).
Animal models are always the first choice in the attempt 
to imitate the endogenous condition, but because of size 
differences, joint thickness and healing potential, the results 
are difficult to extrapolate to humans (Sakata et al., 2015). 
Despite this drawback, MSC are more suitable since their 
therapeutic potential can be explained by two properties: 
(1) their capability of homing/migration, incorporation and 
further differentiation within the host, and (2) a battery 
of morphogens, chemokines and factors secreted by the 
MSC (Pak et al., 2018). This second characteristic is being 
currently harnessed to treat essentially knee and hip joints in 
osteoarthritis by intra-articular injection (Desando et al., 2013; 
Zhang et al., 2016; Cosenza et al., 2017; Seong et al., 2017).
Some other therapies applied for joint regeneration are 
microfractures, which consists in a procedure using special 
instruments that are inserted through small incisions in 
the underlying bone to induce the healing response, and 
‘autologous chondrocyte implantation’ (ACI) in which 
chondrocytes are isolated from the low-weight-bearing 
part of a healthy joint and culture expanded in vitro. The 
liability of these methods relies in that microfractures can 
lead to fibrocartilage formation, and primary monolayer 
chondrocytes cultures tend to dedifferentiate them, which 
contributes to loss of its chondral characteristics, acquiring 
fibroblastoid morphology (Nam et al., 2018). 
A new state-of-the-art technology to help cure joint 
injuries is the 3D bioprinting of cell droplets embedded on 
a scaffold. The deposition of the bioink, in turns, has to be 
controlled, cytocompatible, bioresorbable and satisfy the ECM 
features. Most suitable scaffolds for cartilage regeneration are 
composed of hydrogel, since gel consistency allows the mixing 
of the cells with growth factors and provide the lubrication 
characteristic, contributing to the cells commitment towards 
the chondrogenic phenotype (Roseti et al., 2018).
Plastic and reconstructive surgery
One of the most commonly performed procedures in this 
medical field is the transplantation of autologous fat graft, 
where lipoaspirated adipose tissue is reinjected without any 
previous process to separate different populations of cells. It 
is usually used in reconstructive and aesthetic surgery to fill 
defects and promote graft volume for tissue augmentation 
(Kaufman, 2007). This method has been improved by 
Matsumoto, who enriched the lipoinjection with SVF cells 
in order to promote a better engraftment of the implant 
(Matsumoto et al., 2006). The engraftment is thought to occur 
by the ASC’s promoting revascularization properties during 
the acute phase of transplantation (Blanton et al., 2009). This 
procedure is advantageous because the adipose tissue from 
one reservoir of the body is removed and reimplanted in 
another site during a single surgery (Lin et al., 2008). On the 
other hand, this kind of reimplantation implies a serious risk, 
since it is likely to occur necrosis or resorption of the grafted 
fat  (Coleman, 1995; Eto et al., 2012).
MSC are also applied in the treatment of chronic non-
healing cutaneous lesions such as fistulae in Crohn’s disease, 
skin necrosis, tissue ischemia caused by previous irradiation, 
and burns. It has been suggested that hASC can improve 
skin healing because they have the ability to differentiate 
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into endothelial progenitor cells, since they secrete vascular 
endothelial growth factor (VEGF),  and have, indeed, a 
periendothelial location within the adipose tissue (Traktuev et 
al., 2008; Hsiao et al., 2012). This skin recovery characteristic is 
also attributed to the fact that hASC have immunomodulatory 
effects, which is given by their capacity to secrete cytokines, 
which confers them pro-coagulant and neo-angiogenic 
properties (Moll et al., 2012; Kapur and Katz, 2013). Another 
interesting feature about the ASC in wound healing is that 
they have shown to diminish excessive scar formation, 
improve color and scar pliability, associated with their anti-
inflammatory response (González et al., 2009; Yun et al., 2012).
Finally, when the injured areas are too large or relatively 
deep, the use of  scaffolds immersed in a cell suspension (Kim 
and Jeong, 2014) is required. In Argentina, the first clinical 
trial for the treatment of large burn injury, approved by the 
INCUCAI is now on progress. This trial consists in the local 
and topical application of cadaveric BMSC through a fibrin-
based polymer spray covering an acellular dermal biological 
matrix (Mansilla et al., 2012). Importantly, this trial is being 
performed with allogenic MSC instead of autologous ones. 
An unsolved question regarding their use in skin 
regeneration is whether the application of living MSC is 
needed, since according to Wang et al., (2017) their usefulness 
seems to be mainly based on their secretory vesicles.
Conclusions
From 1912, when Alexis Carrel published the first drawing 
of a stem cell colony obtained in vitro from a chicken 
embryo (Carrel, 1912), to the finding in 2006 of the four 
factors to induce pluripotency in somatic cells by Shinya 
Yamanaka (Takahashi and Yamanaka, 2006), we have gone 
through a relatively slow  period of learning on stem cells. 
But, in the last 12 years, along with advances in cell biology 
instrumentation and informatics, we have witnessed a great 
leap in our knowledge of stem cells potential.
Currently, there are almost five thousand clinical trials 
with stem cells from different sources. Of these, at least 
two thousand are being carried out with adult MSC, which 
highlights their utility. As we have already explained, ASC 
are a subtype of MSC, showing lots of advantages over other 
stem cells. Starting from the bioethical concerns regarding 
the use of embryonic stem cells, and continuing with ASC’s 
greater yields, the identical capability of differentiation to 
other MSC and lack of MHCII in their surface, that allows 
allogenic transplantation without rejection, they suppose 
one of the most taking-into-account models to be applied in 
regenerative medicine.
ASC treatments have been proposed for a variety 
of diseases including musculoskeletal (osteoarthritis, 
rheumatoid arthritis, osteogenesis imperfecta), cardiac (heart 
failure, arrhythmia, myocardial infarction), neurological 
(Parkinson’s disease, Amyotrophic Lateral Sclerosis, multiple 
sclerosis, Alzheimer’s disease, schizophrenia), metabolic 
(Type I and II Diabetes), and hepatic diseases (liver cirrhosis). 
Several of the ongoing approaches in regenerative medicine, 
consider strikingly diverse parameters that influence the 
biological outcome within the niche of the target tissue. 
This adds complexity to the equation by introducing 
various professions (biologists, physicians and materials 
engineers), to combine their expertises in a single area (tissue 
engineering), for the creation of more effective treatments 
(Beldjilali-Labro et al., 2018).
One of greatest concerns regarding the ASC applications 
in medicine is that they may promote tumor growth, which 
has been shown in some studies where tumor cells proliferate 
more under ASC-conditioned medium or in co-culture of 
ASC with prostate cancer cells (Yu et al., 2008; Prantl et al., 
2010). This fact is not surprising, since it has been proved 
that they secrete VEGF, which could stimulate metastases by 
generating new blood vessels within the tumor.
Although the use of ASC is quite promising, we must 
not disregard the need of adequate scientific groundings, for 
both their in vitro and in vivo handling, and stick to stringent 
laboratory good practices, like the use of non-xenogenic 
animal-derived products, to ensure optimal clinical results.
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